Fierce Biotech: Oramed phase 2 insulin drug data ‘paint an exciting picture’ in rocky NASH landscape September 13, 2022 In the News
The Pharma Letter: Huge potential for oral insulin candidate, says Oramed CEO Nadav Kidron September 3, 2018 In the News